{"id":"efanesoctacog-alpha","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Thrombotic events"},{"rate":null,"effect":"Inhibitor development"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug is designed for hemophilia B (Factor IX deficiency) by providing a bypass mechanism that allows Factor IXa to activate Factor X independently of the missing Factor VIII cofactor. It functions as a Factor IXa-Factor X fusion protein, effectively restoring the amplification phase of the coagulation cascade. This approach enables hemostasis without requiring Factor IX replacement or Factor VIII supplementation.","oneSentence":"Efanesoctacog alpha is a recombinant fusion protein that bridges Factor IXa and Factor X to restore the intrinsic tenase complex activity in patients with hemophilia B.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:40:22.524Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia B (Factor IX deficiency) for routine prophylaxis and treatment of bleeding episodes"}]},"trialDetails":[{"nctId":"NCT07158606","phase":"PHASE4","title":"Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction","status":"NOT_YET_RECRUITING","sponsor":"Versiti Blood Health","startDate":"2025-10-01","conditions":"Hemophilia A With Inhibitor","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"efanesoctacog alpha","genericName":"efanesoctacog alpha","companyName":"Versiti Blood Health","companyId":"versiti-blood-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Efanesoctacog alpha is a recombinant fusion protein that bridges Factor IXa and Factor X to restore the intrinsic tenase complex activity in patients with hemophilia B. Used for Hemophilia B (Factor IX deficiency) for routine prophylaxis and treatment of bleeding episodes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}